Skip to main content
. 2016 Jan 29;7(8):9513–9524. doi: 10.18632/oncotarget.7069

Figure 1. Silencing of CABYR-a/b enhances TRAIL-induced apoptosis in lung cancer cells.

Figure 1

Expression of CABYR-a/b in H460 and A549 cells was determined by RT-PCR and western blotting (A). Cell survival rates were measured by the MTT assay following treatment with the indicated concentrations of TRAIL for 12 h (B) or 24 h (C) in CABYR-a/b-silenced and control H460 cells. The cell survival percentage was obtained in comparison with that of the respective control cells. The apoptotic percentage was measured using PE/7-AAD staining and analyzed by flow cytometry in CABYR-a/b-silenced and control cells treated with 20 ng/mL TRAIL for 6 h in H460 cells or 200 ng/mL for 24 h in A549 cells. 0.1% BSA was used as negative control (D). The histograms demonstrate the apoptotic rates of NCI-H460 and A549 cells (E). Re-introduction of CABYR-a in shRNA cells partially restored cells TRAIL resistance in response to similar concentrations of TRAIL (F). Histograms demonstrate the apoptotic rates of cells (G). The results represent the means of at least three independent experiments. *p < 0.05 and **p < 0.01 for the comparisons of the experimental and control groups. β-Actin was used as an internal control to ensure equal protein loading.